Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
2.080
-0.130 (-5.88%)
At close: Nov 13, 2026, 4:00 PM EST
2.150
+0.070 (3.37%)
After-hours: Nov 13, 2026, 7:13 PM EST
Genprex Employees
Genprex had 13 employees as of December 31, 2025. The number of employees decreased by 3 or 18.75% compared to the previous year. That makes Genprex the 39,615th largest employer in the world and 5,829th in the United States.
Employees
13
Change (1Y)
-3
Growth (1Y)
-18.75%
Revenue / Employee
n/a
Profits / Employee
-$1,269,120
Market Cap
1.70M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 13 | -3 | -18.75% | 13 | 0 |
| Sep 30, 2025 | 13 | -6 | -31.58% | 13 | 0 |
| Jun 30, 2025 | 15 | -6 | -28.57% | 15 | 0 |
| Mar 31, 2025 | 15 | -11 | -42.31% | 15 | 0 |
| Dec 31, 2024 | 16 | -10 | -38.46% | 16 | 0 |
| Sep 30, 2024 | 19 | -12 | -38.71% | 19 | 0 |
| Jun 30, 2024 | 21 | -9 | -30.00% | 21 | 0 |
| Dec 31, 2023 | 26 | -2 | -7.14% | 26 | 0 |
| Sep 30, 2023 | 31 | 9 | 40.91% | 31 | 0 |
| Jun 30, 2023 | 30 | 8 | 36.36% | 30 | 0 |
| Mar 31, 2023 | 28 | 9 | 47.37% | 28 | 0 |
| Dec 31, 2022 | 28 | 11 | 64.71% | 28 | 0 |
| Sep 30, 2022 | 22 | 6 | 37.50% | 22 | 0 |
| Jun 30, 2022 | 22 | 6 | 37.50% | 22 | 0 |
| Mar 31, 2022 | 19 | 7 | 58.33% | 19 | 0 |
| Dec 31, 2021 | 17 | 5 | 41.67% | 17 | 0 |
| Sep 30, 2021 | 16 | 4 | 33.33% | 16 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Enlivex | 34 |
| PMGC Holdings | 34 |
| VivoSim Labs | 15 |
| BioRestorative Therapies | 14 |
| Kairos Pharma | 4 |
| 60 Degrees Pharmaceuticals | 3 |
| Oragenics | 3 |
GNPX News
- 2 days ago - Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium - PRNewsWire
- 8 days ago - Genprex’s Reqorsa Gene Therapy shows cellular repair efficacy - TheFly
- 8 days ago - Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress - PRNewsWire
- 9 days ago - Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer - PRNewsWire
- 16 days ago - Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting - PRNewsWire
- 23 days ago - Genprex highlights new peer-reviewed research on TUSC2 tumor suppressor gene - TheFly
- 23 days ago - Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging - PRNewsWire
- 2 months ago - Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PRNewsWire